Amyloid beta
4 drugs CNS
3
approved indications
4
Approved Drugs
3
Companies
8
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (3 companies)
✓ All 4 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (8 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
EISAI INC 2 drugs
Eli Lilly 1 drug
GE HEALTHCARE 1 drug
By Therapeutic Area
Other 2 drugs
CNS 2 drugs
Drugs by Company PRO
By Therapeutic Area
Other 2 drugs
KISUNLA, LEQEMBI
CNS 2 drugs
VIZAMYL, LEQEMBI IQLIK
Indications Treated
Alzheimer's DiseaseCognitive DeclineAlzheimer's diseaseMild cognitive impairmentMild dementia stage of Alzheimer's diseaseAlzheimer’s diseaseMild cognitive impairment stage of Alzheimer’s diseaseMild dementia stage of Alzheimer’s disease
All Drugs Targeting Amyloid beta
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| KISUNLA | Eli Lilly | 2024 | 3 | |
| LEQEMBI | EISAI INC | 2023 | 3 | |
| VIZAMYL | GE HEALTHCARE | 2013 | 2 | CNS |
| LEQEMBI IQLIK | EISAI INC | 2025 | 1 | CNS |